[go: up one dir, main page]

DE60318182D1 - Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe - Google Patents

Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe

Info

Publication number
DE60318182D1
DE60318182D1 DE60318182T DE60318182T DE60318182D1 DE 60318182 D1 DE60318182 D1 DE 60318182D1 DE 60318182 T DE60318182 T DE 60318182T DE 60318182 T DE60318182 T DE 60318182T DE 60318182 D1 DE60318182 D1 DE 60318182D1
Authority
DE
Germany
Prior art keywords
dihydroxy
esters
pulmonary delivery
aerosol formulations
estratriene derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318182T
Other languages
English (en)
Other versions
DE60318182T2 (de
Inventor
Rebecca Jaine Davies
David Ganderton
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Alessandra Ferraris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of DE60318182D1 publication Critical patent/DE60318182D1/de
Application granted granted Critical
Publication of DE60318182T2 publication Critical patent/DE60318182T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60318182T 2002-03-01 2003-02-24 Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe Expired - Lifetime DE60318182T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02004787 2002-03-01
EP02004787A EP1340503A1 (de) 2002-03-01 2002-03-01 Lösung Aerosol Formulierung von Estern von 3,17-dihydroxy Oestratrien-Derivaten zur Lungenverabreichung
PCT/EP2003/001856 WO2003074058A1 (en) 2002-03-01 2003-02-24 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery

Publications (2)

Publication Number Publication Date
DE60318182D1 true DE60318182D1 (de) 2008-01-31
DE60318182T2 DE60318182T2 (de) 2008-12-04

Family

ID=27675680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318182T Expired - Lifetime DE60318182T2 (de) 2002-03-01 2003-02-24 Aerosol-formulierungen mit estern von 3,17-dihydroxyöstratrien-derivaten zur pulmonalen abgabe

Country Status (9)

Country Link
US (1) US20050209207A1 (de)
EP (2) EP1340503A1 (de)
AT (1) ATE381339T1 (de)
AU (1) AU2003215588A1 (de)
BR (1) BR0303347A (de)
DE (1) DE60318182T2 (de)
ES (1) ES2297183T3 (de)
NO (1) NO20034873L (de)
WO (1) WO2003074058A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1100723A2 (en) * 2011-12-28 2013-06-28 Avidin Kft Use of estrogen derivatives for preparing medicament for the treatment of psychiatric diseases
WO2025039045A1 (en) * 2023-08-23 2025-02-27 Inhaler Supplies Pty Ltd Inhalable formulation for volatile actives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1099722A (en) * 1964-04-20 1968-01-17 Takeda Chemical Industries Ltd Aerosol
DE2758549A1 (de) * 1977-12-23 1979-07-05 Schering Ag Pharmazeutische zubereitung
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US5043331A (en) * 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
AU658854B2 (en) * 1990-10-18 1995-05-04 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
EP1027057A4 (de) * 1997-10-28 2003-01-02 Vivus Inc Behandlung von weibliche sexuelle störungen
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Also Published As

Publication number Publication date
EP1480651B1 (de) 2007-12-19
AU2003215588A1 (en) 2003-09-16
ATE381339T1 (de) 2008-01-15
BR0303347A (pt) 2004-07-13
NO20034873L (no) 2003-12-23
EP1340503A1 (de) 2003-09-03
NO20034873D0 (no) 2003-10-31
WO2003074058A1 (en) 2003-09-12
EP1480651A1 (de) 2004-12-01
DE60318182T2 (de) 2008-12-04
ES2297183T3 (es) 2008-05-01
US20050209207A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
CY1122851T1 (el) Υπερλεπτο σκευασμα φορμοτερολης
DK1389137T3 (da) Sammensætninger til lungelægemiddellevering af protein
DK0616525T3 (da) Medikamenter
SE0102276D0 (sv) Device and method for the administration of a medicament
CO4940408A1 (es) Composicion de aerosol farmaceutico
PT918507E (pt) Formulacoes em aerossol
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
GB9425160D0 (en) Medicaments
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
YU2494A (sh) Farmaceutska formulacija za tretiranje zavisnosti od nikotina
ATE395071T1 (de) Pharmazeutische zubereitungen zur angiogenese- therapie
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
GB0323684D0 (en) Improvements in or relating to organic compounds
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
BG107257A (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
ATE381339T1 (de) Aerosol-formulierungen mit estern von 3,17- dihydroxyöstratrien-derivaten zur pulmonalen abgabe
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
ECSP971997A (es) Nueva formulacion de un producto farmaceutico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition